2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis

Show other versions (2)

<strong>Objective</strong>. To develop an evidence- based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). <strong>Methods&...

Full description

Bibliographic Details
Main Authors:	Singh, J, Guyatt, G, Ogdie, A, Gladman, D, Deal, C, Deodhar, A, Dubreuil, M, Dunham, J, Husni, M, Kenny, S, Kwan-Morley, J, Lin, J, Marchetta, P, Mease, P, Merola, J, Miner, J, Ritchlin, C, Siaton, B, Smith, B, Van Voorhees, A, Jonsson, A, Shah, A, Sullivan, N, Turgunbaev, M, Coates, L, Gottlieb, A, Magrey, M, Nowell, W, Orbai, A, Reddy, S, Scher, J, Siegel, E, Siegel, M, Walsh, J, Turner, A, Reston, J
Format:	Journal article
Language:	English
Published:	Wiley 2018

Similar Items

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
by: Singh, J, et al.
Published: (2018)

2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis
by: Singh, JA, et al.
Published: (2018)

Classification and outcome measures for psoriatic arthritis
by: Leung, Y, et al.
Published: (2018)

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies
by: Tillett, W, et al.
Published: (2017)

GRAPPA 2017 Project Report
by: Callis Duffin, K, et al.
Published: (2018)

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
by: Coates, LC, et al.
Published: (2024)

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
by: Atul Deodhar, et al.
Published: (2019-10-01)

Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
by: Leung, YY, et al.
Published: (2020)

Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1 year results from two phase 3 studies
by: Gossec, L, et al.
Published: (2024)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
by: Strand, V, et al.
Published: (2024)

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study
by: Alexis Ogdie, et al.
Published: (2024-05-01)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
by: Helliwell, PS, et al.
Published: (2022)

Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
by: Leung, YY, et al.
Published: (2021)

Outcomes of the 2019 GRAPPA workshop on continuous composite indices for the assessment of psoriatic arthritis and membership: Recommended next steps
by: Tillett, W, et al.
Published: (2020)

Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review
by: Leung, Y-Y, et al.
Published: (2020)

OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF
by: Leung, Y-Y, et al.
Published: (2021)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

International treatment recommendations update: A report from the GRAPPA 2016 annual meeting
by: Coates, L, et al.
Published: (2017)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
by: Alexis Ogdie, et al.
Published: (2023-05-01)

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 annual meeting: report and plan for completing the core outcome measurement set
by: Leung, Y, et al.
Published: (2019)

Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT Working Group
by: Leung, Y-Y, et al.
Published: (2023)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
by: Coates, L, et al.
Published: (2020)

Classification and Outcome Measures for Psoriatic Arthritis
by: Ying Ying Leung, et al.
Published: (2018-09-01)

The extension of the litosphere north of Scotland
by: T. J. Reston
Published: (1993-06-01)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

How serotonin shapes moral judgment and behavior
by: Siegel, J, et al.
Published: (2013)

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
by: Gossec, L, et al.
Published: (2024)

Phytoplankton Community Composition Determined From Co-variability Among Phytoplankton Pigments From the NAAMES Field Campaign
by: Sasha J. Kramer, et al.
Published: (2020-04-01)

Technical Note: Particulate reactive oxygen species concentrations and their association with environmental conditions in an urban, subtropical climate
by: S. S. Khurshid, et al.
Published: (2014-07-01)

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
by: Robert Landewé, et al.
Published: (2024-02-01)

Social uncertainty is heterogeneous and sometimes valuable
by: Kappes, A, et al.
Published: (2019)

Computational mechanisms of moral inference
by: Siegel, J
Published: (2019)

Evaluation of Aeris mid-infrared absorption (MIRA), Picarro CRDS (cavity ring-down spectroscopy) G2307, and dinitrophenylhydrazine (DNPH)-based sampling for long-term formaldehyde monitoring efforts
by: A. P. Mouat, et al.
Published: (2024-04-01)

Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative
by: Antony, A, et al.
Published: (2021)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
by: Atul Deodhar, et al.
Published: (2022-07-01)

NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia
by: John A. Saunders, et al.
Published: (2012-04-01)

Content and face validity and feasibility of 5 candidate instruments for psoriatic arthritis randomized controlled trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
by: Holland, R, et al.
Published: (2018)

Plasma Imaging and Optimization of Energy Deposition during Femtosecond-laser Processing
by: Solis J., et al.
Published: (2013-11-01)

Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis
by: Philip Mease, et al.
Published: (2022-12-01)

An update on the management of axial spondyloarthritis for sports medicine professionals
by: Abhijeet Danve, et al.
Published: (2024-10-01)